st year. Revenues from sales of consumables, which include reagent discs, hematology reagent kits, VS
pro specialty cartridges, i-STAT cartridges and rapid tests, increased by an aggregate of $6.0 million, or 22 percent, over the same period last year. Abaxis reported net income of $5.0 million for the fiscal quarter ended December 31, 2012, compared to $2.9 million for the same period last year, an increase of 75 percent. Abaxis' effective tax rate in the quarter ended December 31, 2012 was 38 percent, compared to 37 percent for the same period last year. Abaxis reported diluted net income per share of $0.22 (calculated based on 22,341,000 shares) for the three-month period ended December 31, 2012, compared to $0.13 per share (calculated based on 21,990,000 shares) for the same period last year.
Nine-Month Results: For the nine-month period ended December 31, 2012, Abaxis reported revenues of $136.1 million, as compared with revenues of $113.9 million for the comparable period last year, an increase of 19 percent. Revenues from instrument sales increased by an aggregate of $10.1 million, or 40 percent, over the same period last year. Revenues from consumables increased by an aggregate of $8.7 million, or 10 percent, over the same period last year. The company reported net income of $20.8 million, including gain from the company's litigation settlement in the second quarter of fiscal 2013, compared to $8.4 million for the same period last year. The company's effective tax rate in the nine-month period ended December 31, 2012, was 38 percent, compared to 37 percent for the same period last year. The company reported diluted net income per share of $0.93 (calculated based on 22,316,000 shares) for the nine-month period ended December 31, 2012, compared to $0.37 per share (calculated based on 22,579,000 shares) for the same period last year.
Other Reported Information: T
'/>"/>
SOURCE Abaxis, Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related medicine technology :1.
Abaxis To Report Third Quarter Fiscal Year 2013 Financial Results Thursday, January 31, 20132.
Abaxis Declares Special Cash Dividend of $1.00 Per Share3.
Abaxis, Inc. to Present at 24th Annual Piper Jaffray Healthcare Conference4.
Abaxis, Inc. to Participate in Sidoti & Companys Inaugural One-on-One Conference5.
Abaxis, Inc. to Present at the Stephens Fall Investment Conference6.
Abaxis, Inc. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference7.
Abaxis Announces Exclusive Distribution Agreement with Abbott8.
Abaxis Announces the Launch of Kidney Profile Plus Panel9.
Abaxis, Inc. to Present at UBS Global Life Sciences Conference10.
Abaxis, Inc. to Present at CL Kings 10th Annual Best Ideas Conference 201211.
Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference